帕博利珠单抗治疗BCG无反应性原位癌的成本效果分析
本研究采用决策分析马尔可夫模型,从美国Medicare支付方角度、5年时间 horizon,比较帕博利珠单抗、挽救性膀胱内化疗(吉西他滨-多西他赛诱导+月度维持)与根治性膀胱切除术,用于BCG无反应性原位癌且为根治性膀胱切除术候选者(索引患者1)或不情愿/无法接受根治性膀胱切除术者(索引患者2)。结果显示,按现行价格,帕博利珠单抗相对于根治性膀胱切除术或挽救性膀胱内化疗均不具有成本效果。
要点
- 帕博利珠单抗相对于根治性膀胱切除术的ICER为$1,403,008/QALY,不具有成本效果。
- 帕博利珠单抗相对于挽救性膀胱内化疗的ICER为$2,011,923/QALY,不具有成本效果。
- 挽救性膀胱内化疗在<5年时间 horizon 内相对于根治性膀胱切除术具有成本效果。
核心结论
- 按现行价格,帕博利珠单抗对BCG无反应性原位癌相对于根治性膀胱切除术或挽救性膀胱内化疗均不具有成本效果。
- 挽救性膀胱内化疗在5年时相对于根治性膀胱切除术接近具有成本效果(ICER $118,324/QALY)。
研究设计与样本
- 研究使用决策分析马尔可夫模型,从美国Medicare支付方角度、5年时间 horizon 进行分析。
- 比较帕博利珠单抗、挽救性膀胱内化疗(吉西他滨-多西他赛诱导+月度维持)与根治性膀胱切除术。
- 目标人群为BCG无反应性原位癌患者:索引患者1为根治性膀胱切除术候选者,索引患者2为不情愿或无法接受根治性膀胱切除术者。
- 采用意愿支付阈值$100,000/QALY比较增量成本效果比,并行单因素和概率敏感性分析。
主要发现
- 索引患者1中,帕博利珠单抗相对于根治性膀胱切除术的ICER为$1,403,008/QALY,相对于挽救性膀胱内化疗的ICER为$2,011,923/QALY。
- 单因素敏感性分析显示,帕博利珠单抗价格需降低>93%才相对于根治性膀胱切除术具有成本效果。
- 挽救性膀胱内化疗相对于根治性膀胱切除术在<5年时间 horizon 内具有成本效果,5年时ICER为$118,324/QALY。
- 单因素敏感性分析显示,若2年复发风险<55%或转移风险<5.9%,挽救性膀胱内化疗相对于根治性膀胱切除术具有成本效果。
- 索引患者2中,帕博利珠单抗需降价>90%才具有成本效果(ICER $1,073,240/QALY)。
关键数值与推荐
- 意愿支付阈值为$100,000/QALY。
- 帕博利珠单抗相对于根治性膀胱切除术的ICER为$1,403,008/QALY(索引患者1)。
- 帕博利珠单抗相对于挽救性膀胱内化疗的ICER为$2,011,923/QALY(索引患者1)。
- 挽救性膀胱内化疗相对于根治性膀胱切除术的ICER为$118,324/QALY(5年时)。
- 帕博利珠单抗价格需降低>93%才相对于根治性膀胱切除术具有成本效果(索引患者1)。
临床怎么用
- 对于BCG无反应性原位癌且适合根治性膀胱切除术的患者,帕博利珠单抗在当前价格下不具有成本效果。
- 挽救性膀胱内化疗(吉西他滨-多西他赛)在<5年时间 horizon 内相对于根治性膀胱切除术具有成本效果。
- 帕博利珠单抗仅在价格大幅降低(>90%–93%)时才可能具有成本效果。
局限性
- 模型基于美国Medicare支付方角度和5年时间 horizon,结果可能不适用于其他医疗体系或更长时限。
- 成本效果结论高度依赖于帕博利珠单抗价格和复发/转移风险假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with bacillus Calmette-Guérin-unresponsive carcinoma in situ are treated with radical cystectomy or salvage intravesical chemotherapy. Recently, pembrolizumab was approved for bacillus Calmette-Guérin-unresponsive carcinoma in situ. MATERIALS AND METHODS: We used a decision-analytic Markov model to compare pembrolizumab, salvage intravesical chemotherapy (with gemcitabine-docetaxel induction+monthly maintenance) and radical cystectomy for patients with bacillus Calmette-Guérin-unresponsive carcinoma in situ who are radical cystectomy candidates (index patient 1) or are unwilling/unable to undergo radical cystectomy (index patient 2). The model used a U.S. Medicare perspective with a 5-year time horizon. One-way and probabilistic sensitivity analyses were performed. Incremental cost-effectiveness ratios were compared using a willingness to pay threshold of $100,000/quality-adjusted life year. RESULTS: For index patient 1, pembrolizumab was not cost-effective relative to radical cystectomy (incremental cost-effectiveness ratios $1,403,008/quality-adjusted life year) or salvage intravesical chemotherapy (incremental cost-effectiveness ratios $2,011,923/quality-adjusted life year). One-way sensitivity analysis revealed that pembrolizumab only became cost-effective relative to radical cystectomy with a >93% price reduction. Relative to radical cystectomy, salvage intravesical chemotherapy was cost-effective for time horizons <5 years and nearly cost-effective at 5 years (incremental cost-effectiveness ratios $118,324/quality-adjusted life year). One-way sensitivity analysis revealed that salvage intravesical chemotherapy became cost-effective relative to radical cystectomy if risk of recurrence or metastasis at 2 years was less than 55% or 5.9%, respectively. For index patient 2, pembrolizumab required >90% price reduction to be cost-effective (incremental cost-effectiveness ratios $1,073,240/quality-adjusted life year). Pembrolizumab was cost-effective in 0% of 100,000 microsimulations in probabilistic sensitivity analyses for both index patients. CONCLUSIONS: At its current price, pembrolizumab is not cost-effective for bacillus Calmette-Guérin-unresponsive carcinoma in situ relative to radical cystectomy or salvage intravesical chemotherapy. Although gemcitabine-docetaxel is not cost-effective relative to radical cystectomy at 5 years, further studies may validate its cost-effectiveness if recurrence and metastasis thresholds are met.
引用
- Wymer KM, Sharma V, Saigal CS, et al. Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder. J Urol. 2020. PMID: 33347775. doi:10.1097/JU.0000000000001515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。